Medical Epigenetics Volume 29

Medical Epigenetics, Second Edition provides a comprehensive analysis of epigenetics in health management, across a broad spectrum of disease categories and specialties, and with a focus on human systems, epigenetic diseases that affect these systems, and evolving modes of epigenetic-based treatment. Here, more than 40 leading researchers examine how each human system is affected by epigenetic maladies, offering an all-in-one resource on medical epigenetics not only for those directly involved with health care, but investigators in life sciences, biotech companies, graduate students, and others who are interested in applied aspects of epigenetics. Incorporating both diagnostic and prognostic epigenetic approaches, this volume also fully supports the application of epigenetics in precision medicine.

This second edition of Medical Epigenetics, a volume in the Translational Epigenetics series, has been fully revised to address recent advances in disease epigenetics and role of epigenetics in precision medicine, with all-new chapters on skin cancer epigenetics, network analysis in medical epigenetics, machine learning in epigenetic diseases, and clinical trials of epigenetics drugs.

Section A Overview
1. Advances in medical epigenetics
Section B General medical aspects of epigenetics
2. Environmental epigenetic epidemiology
3. Lifestyle and preventive medical epigenetics
4. Environmental medical epigenetics: A review of epigenetically induced medical risks generated from exposures in our air, food, and personal products
5. Behavioral medical epigenetics
6. Medical epigenetics and twins
7. Epigenetic biomarkers of disease
8. Prognostic epigenetics
Section C Epigenetics of system disorders
9. Autoimmune disease and epigenetics
10. Epigenetics of pulmonary diseases
11. Cardiovascular disorders and epigenetics
12. Epigenomics of intestinal disease
13. Epigenetics of skin disorders
14. Epigenetics in bone and joint disorders
15. Epigenetics of muscle disorders
16. Reproductive disease epigenetics
17. Epigenetics in ocular medicine
Section D Multi-system medical epigenetics
18. Pediatric diseases and epigenetics
19. Epigenetics of infectious diseases
20. Clinical utility of solid tumor epigenetics
21. Epigenetics in acute myeloid leukemia
22. Epigenetic regulation in cancer metastasis
23. Epigenetics in exercise science and sports medicine
Section E Bioinformatics of epigenetic medicine
24. Machine learning in epigenetic diseases
Section F Pharmacology of epigenetics
25. Epigenetics in toxicology and drug development
26. Pharmacoepigenomics in neurodegenerative diseases
Section G Therapeutic epigenetics
27. Therapeutics and DNA methylation inhibitors
28. Histone deacetylase inhibitors in medical therapeutics
29. Sirtuins as NAD+-dependent deacetylases and their potential in medical therapy
30. Experimental approaches toward histone acetyltransferase modulators as therapeutics
31. Histone methylation modifiers in medical therapeutics
32. Modulation of noncoding RNAs (ncRNAs) and their potential role as therapeutics
33. Nutrients and phytonutrients as promising epigenetic nutraceuticals
34. Epigenetics of pain management
35. Precision medical epigenetics
36. Epigenetics and regenerative medicine
37. Stem cell epigenetics in medical therapy
38. The clinical landscape of HDAC inhibitors
Section H Medical epigenetics: Future prospects
39. Epigenetics: Future prospective in human disorders and therapeutics
40. Prospective advances in medical epigenetics

Dr. Tollefsbol is a Distinguished Professor of Biology and a Senior Scientist in the O'Neal Comprehensive Cancer Center, Integrative Center for Aging Research, Nutrition Obesity Research Center, University Wide Microbiome Center, and the Comprehensive Diabetes Center at the University of Alabama at Birmingham (UAB). He is Director of the UAB Cell Senescence Culture Facility which he established in 1999. Dr. Tollefsbol trained as a Postdoctoral Fellow and Assistant Research Professor with members of the National Academy of Science at Duke University and the University of North Carolina. He earned doctorates in molecular biology and osteopathic medicine from the University of North Texas Health Sciences Center and his bachelor's degree in Biology from the University of Houston. He has received prior funding from the NCI, NHLBI, NIMH and other federal institutes as well as the Glenn Foundation for Medical Research, Susan G. Komen for the Cure, the American Federation for Aging Research (AFAR), and the American Institute for Cancer Research (AICR) among many other sources.